Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes | Zendy

Michelle L. O’Donoghue | Zendy; Deepak L. Bhatt | Zendy; Stephen D. Wiviott | Zendy; Shaun G. Goodman | Zendy; Desmond J. Fitzgerald | Zendy; Dominick J. Angiolillo | Zendy; Shinya Goto | Zendy; Gilles Montalescot | Zendy; Uwe Zeymer | Zendy; Philip E. Aylward | Zendy; Victor Guetta | Zendy; Dariusz Dudek | Zendy; Rafal Ziȩcina | Zendy; Charles F. Contant | Zendy; Marcus Flather | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Safety and Tolerability of Atopaxar in the Treatment of Patients With Acute Coronary Syndromes

Author(s) -

Michelle L. O’Donoghue,

Deepak L. Bhatt,

Stephen D. Wiviott,

Shaun G. Goodman,

Desmond J. Fitzgerald,

Dominick J. Angiolillo,

Shinya Goto,

Gilles Montalescot,

Uwe Zeymer,

Philip E. Aylward,

Victor Guetta,

Dariusz Dudek,

Rafal Ziȩcina,

Charles F. Contant,

Marcus Flather

Publication year - 2011

Publication title -

circulation

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 7.795

H-Index - 607

eISSN - 1524-4539

pISSN - 0009-7322

DOI - 10.1161/circulationaha.110.000786

Subject(s) - medicine , placebo , tolerability , myocardial infarction , stroke (engine) , angina , anesthesia , unstable angina , clopidogrel , cardiology , adverse effect , mechanical engineering , engineering , alternative medicine , pathology

Atopaxar (E5555) is a reversible protease-activated receptor-1 thrombin receptor antagonist that interferes with platelet signaling. The primary objective of the Lessons From Antagonizing the Cellular Effects of Thrombin-Acute Coronary Syndromes (LANCELOT—ACS) trial was to evaluate the safety and tolerability of atopaxar in patients with ACS.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research